MultiplexDX is excited to announce our participation in the San Antonio Breast Cancer Symposium (SABCS) 2024, where we presented our groundbreaking research on the topic: “An Observational Cohort Study of Multiplex8+: A Spatially Informed Assay that Uses Multiplexed RNA-FISH Guided Laser Capture Microdissection Followed by Total RNA-Sequencing.”

Our study demonstrated the feasibility of implementing Multiplex8+ in a real-world clinical setting, with significant potential for predicting patient responses to various treatments. In our large-scale retrospective cohort of 1,082 breast tissue samples, Multiplex8+ showed impressive concordance with traditional immunohistochemistry (IHC) methods, achieving 91% alignment, and a 93% accuracy rate overall. By examining gene expression related to antibody-drug conjugate (ADC) antigens, cytotoxic payloads, endocytosis, lysosome function, and resistance mechanisms, we proposed a hypothetical framework for future prospective studies. This approach could be utilized to identify patients most likely to respond to ADC therapies, potentially transforming personalized treatment strategies in breast cancer.

Our research highlights the potential of Multiplex8+ to provide deeper insights into tumor biology and treatment response, offering clinicians a powerful tool for more precise and individualized therapeutic decisions. We look forward to advancing the role of spatial transcriptomics in breast cancer care and contributing to the ongoing dialogue on cancer research innovations at SABCS.

You can find the abstract on page 302 here:
https://sabcs.org/Portals/0/Documents/Formatted_Abstracts%2011-27%20Without%20Embargoed.pdf?ver=vMTqAQGg9YU-Obb3YfuaqQ%3d%3d.

EXPLORE OUR POSTER HERE: SABCS 2024.pdf